Van Hulzen Asset Management LLC increased its stake in shares of CVS Health Corp (NYSE:CVS) by 909.0% in the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 144,629 shares of the pharmacy operator’s stock after acquiring an additional 130,295 shares during the period. CVS Health accounts for 2.1% of Van Hulzen Asset Management LLC’s holdings, making the stock its 9th largest position. Van Hulzen Asset Management LLC’s holdings in CVS Health were worth $7,800,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently bought and sold shares of the stock. Oregon Public Employees Retirement Fund raised its position in CVS Health by 6,858.5% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 25,089,377 shares of the pharmacy operator’s stock valued at $383,000 after purchasing an additional 24,728,818 shares during the last quarter. BlackRock Inc. raised its position in CVS Health by 22.0% in the 4th quarter. BlackRock Inc. now owns 92,954,958 shares of the pharmacy operator’s stock valued at $6,090,409,000 after purchasing an additional 16,757,941 shares during the last quarter. Norges Bank bought a new position in CVS Health in the 4th quarter valued at $840,254,000. FMR LLC raised its position in CVS Health by 30.6% in the 4th quarter. FMR LLC now owns 39,263,265 shares of the pharmacy operator’s stock valued at $2,572,528,000 after purchasing an additional 9,194,005 shares during the last quarter. Finally, Geode Capital Management LLC raised its position in CVS Health by 36.2% in the 4th quarter. Geode Capital Management LLC now owns 16,462,292 shares of the pharmacy operator’s stock valued at $1,076,697,000 after purchasing an additional 4,376,604 shares during the last quarter. Institutional investors and hedge funds own 77.48% of the company’s stock.

Several equities analysts have issued reports on CVS shares. Citigroup set a $74.00 price objective on CVS Health and gave the company a “buy” rating in a research report on Thursday, May 2nd. Argus cut their price objective on CVS Health from $100.00 to $80.00 and set a “positive” rating for the company in a research report on Monday, February 25th. Sanford C. Bernstein started coverage on CVS Health in a research report on Tuesday, March 12th. They issued an “outperform” rating and a $76.00 price objective for the company. Credit Suisse Group downgraded CVS Health from an “outperform” rating to a “neutral” rating and cut their price objective for the company from $73.00 to $61.00 in a research report on Monday, April 29th. Finally, Wells Fargo & Co downgraded CVS Health from an “outperform” rating to a “market perform” rating and cut their price objective for the company from $104.00 to $68.00 in a research report on Wednesday, February 20th. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the stock. CVS Health presently has a consensus rating of “Buy” and a consensus target price of $76.48.

Shares of CVS stock traded down $0.35 on Friday, reaching $54.24. 1,878,002 shares of the stock were exchanged, compared to its average volume of 8,695,746. The company has a market cap of $69.71 billion, a P/E ratio of 7.66, a PEG ratio of 1.08 and a beta of 0.89. CVS Health Corp has a one year low of $51.72 and a one year high of $82.15. The company has a quick ratio of 0.64, a current ratio of 0.95 and a debt-to-equity ratio of 1.45.

CVS Health (NYSE:CVS) last released its earnings results on Wednesday, May 1st. The pharmacy operator reported $1.62 earnings per share for the quarter, topping analysts’ consensus estimates of $1.50 by $0.12. The company had revenue of $61.65 billion during the quarter, compared to the consensus estimate of $60.39 billion. CVS Health had a positive return on equity of 16.80% and a negative net margin of 0.08%. The firm’s quarterly revenue was up 34.8% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.48 earnings per share. As a group, equities research analysts anticipate that CVS Health Corp will post 6.85 earnings per share for the current fiscal year.

WARNING: “Van Hulzen Asset Management LLC Buys 130,295 Shares of CVS Health Corp (NYSE:CVS)” was originally posted by Watch List News and is the sole property of of Watch List News. If you are reading this piece on another domain, it was stolen and reposted in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://www.watchlistnews.com/van-hulzen-asset-management-llc-buys-130295-shares-of-cvs-health-corp-nysecvs/3041655.html.

CVS Health Company Profile

CVS Health Corporation provides health services and plans in the United States. Its Pharmacy Services segment offers pharmacy benefit management solutions, such as plan design and administration, formulary management, retail pharmacy network management, mail order pharmacy, specialty pharmacy and infusion, Medicare Part D, clinical, disease management, and medical spend management services.

Featured Story: Put Option Volume

Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corp (NYSE:CVS).

Institutional Ownership by Quarter for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.